National and Kapodistrian University of Athens
Μελέτη παραγόντων οξειδωτικού stress σε ασθενείς με αγγειακό εγκεφαλικό επεισόδιο (ΑΕΕ)
Abstract
dc:descriptionThe aim of the study was to measure the factors of nitrogen monoxide (NO), hydrogen peroxide PerOx (Η2Ο2), and calprotectin in patients with stroke and and to elucidate their potent correlation with characteristics from patients' history. Patients and Methods. After obtaining the approval from the hospital ethics committee, 42 patients (mean age 72.67 ± 7.851 years) (29 males and 13 females) with acute ischemic stroke (AIS) , who were admitted to the emergency department of General Hospital of Argos between September 2007 and April 2016, were evaluated. Patients, who were diagnosed as having AIS based on medical history, neurological examination findings, and brain CT scans, were included. Information about the study was provided to the patients, and their consent was obtained. Because oxidant levels can change, patients with a history of cerebrovascular disease, neurological disease, chronic kidney disease, blood disorders, or stroke were excluded. 23 participants individuals (mean age 70.91 ± 9.01 years) involved in our study as controls were healthy blood donors and were without any acute or chronic diseases.To assess the dynamic changes in nitric oxide (NO) and calprotectin, EDTA venous blood samples were collected from the patients within the first hour of their hospital admission (t0) and after 8 hours (t1). Serum hydrogen peroxide (PerOx), NO, and calprotectin levels were measured by enzyme-linked immunosorbent assay using commercial assay kits. Because of the NO instability, the amount of NO was indirectly determined by calculating the nitrate to nitrite molar ratio.Statistical analysis was performed using SPSS 23.0 (Windows Version). Paired t-test and Mann–Whitney U test were used accordingly. All performed tests were two sided. A p value less than 0.05 was considered statistically significant (p = 0.05). Results. Forty-two patients (mean age 72.67 ± 7.851 years) with AIS and 23 age-matched healthy control individuals (mean age 70.91 ± 9.01 years) were included. Mean body mass index of the patients was 28.9 (range 20.9–40.4). 64% of the patients who included in the study were hypertensive, while 38% and 23% had a history of diabetes mellitus and coronary artery disease, respectively. Only five patients had documented hyperlipidemia, and four patients had atrial fibrillation. Three patients did not have any comorbidity. Baseline serum levels of NO as nitrate/nitrite concentration were lower in the patients group than those in the control group (−1.870 ± 1.820 vs 0.034 ± 0.048, p < 0.001). After 8 hours, the serum levels of NO (0.949 ± 2.191) were higher than at baseline (−1.870 ± 1.820) in the patients group (p < 0.05). Additionally, serum calprotectin levels were higher at baseline than at t1 in the patients group (12.983 ± 1.377 vs 12.363 ± 0.990 mmol/l, p < 0.01). When the patients were divided into two subgroups depending on their blood pressure, it was found that at baseline, hypertensive patients (64.3%) had lower levels of NO than non-hypertensive patients (−2.387 ± 1.739 vs −0.938 ± 1.624, p = 0.012); this difference was not observed after 8 hours. Moreover, the subdivision of patients into two groups depending on the presence of coronary artery disease (CAD) revealed that patients with CAD (24%) had higher serum levels of NO at t0 and lower serum levels of PerOx at t1 than patients without CAD (p = 0.003 and p = 0.001, respectively). The categorization of patients based on their diabetes mellitus history showed that serum calprotectin levels in diabetic patients (38%) were lower than in non-diabetic patients at baseline (12.215 ± 1.363 vs 13.481 ± 1.170 mmol/l, p = 0.014). This difference was not observed after 8 hours.In terms of pairwise associations, significant positive and negative correlations were found between the measured parameters in the patients and control groups. Conclusion. This study depicts the dynamic changes in the oxidative status at the early stages after AIS incidence and proposes calprotectin as a novel serum biomarker for AIS. This association ferments ground for new implications in both clinical practice and diagnostic techniques.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Chatzopoulos, Antonios
- Χατζόπουλος, Αντώνιος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44048